Genmab — Marts 2018
-
Vi skulle jo gerne nå min. 2 mia i år, så der skal da snart til at være turbo på salget.
-
@hda, ja Q1 med ROW tal der inkluderer fuldt 3 mdr salg i JApan, 4 linje i UK, samt Canada, det skal nok give lidt ekstra
i kassen -
Ja det bliver spændende 17. april.
-
Hvor langt vi kommer over 400 mill. i Q1
-
after reaching €50mio, Dara lost Orphan status in Germany, leading to "eine Bekanntmachung" from the "Bundesministerium für Gesundheit"
https://www.bundesanzeiger.de/ebanzwww/wexsservlet?session.sessionid=16a142094cdbe8edd5841e4fa803c0b8&page.navid=detailsearchlisttodetailsearchdetail&fts_search_list.selected=d747026b6b3fc404&fts_search_list.destHistoryId=16642 https://www.g-ba.de/informationen/nutzenbewertung/307/#tab/beschluesse -
-
Ekstra Bladet om Darzalex salget i US i februar http://borsen.dk/nyheder/virksomheder/artikel/1/360281/genmab_darzalex-salget_faldt_i_usa_i_februar.html?utm_source=forside&utm_campaign=nyhed_03
-
-
The approval is based on results from the TOWER study, which found that BLINCYTO demonstrated a superior improvement in median OS over standard of care (SOC) chemotherapy, nearly doubling median OS. The study showed that median OS was 7.7 months (95 percent CI: 5.6, 9.6) for BLINCYTO versus four months (95 percent CI: 2.9, 5.3) for SOC (hazard ratio for death=0.71; p=0.012). The approval is also based on data from the Phase 2 ALCANTARA study, which evaluated the efficacy of BLINCYTO in adult pat
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind